Dyslipidemia in diabetes mellitus and cardiovascular disease

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Patients with diabetes mellitus (DM) face elevated residual cardiovascular disease (CVD) risk despite statin therapy and lifestyle changes.
• Diabetic dyslipidemia is characterized by high triglycerides, small dense low-density lipoprotein cholesterol (sdLDL-C), and low high-density lipoprotein cholesterol (HDL-C).
• Current combination therapies for diabetic dyslipidemia have limitations and face criticism.

Purpose of the Study:

• To review key clinical trials evaluating the efficacy of combination therapy in reducing CVD risk in patients with diabetic dyslipidemia.
• To assess the risk-benefit profile of available agents used adjunctively with statins for managing dyslipidemia in diabetes.

Main Methods:

• Systematic review of pivotal clinical trials investigating combination therapies for diabetic dyslipidemia.
• Analysis of risk-benefit profiles of agents including niacin, ezetimibe, fenofibrate, and n-3 fatty acids when used with statins.
• Evaluation of emerging therapeutic classes like PCSK9 inhibitors.

Main Results:

• Ezetimibe demonstrates the most favorable risk profile among currently available agents for add-on therapy to statins.
• A recent trial indicated a modest incremental benefit of ezetimibe in reducing CVD risk when added to statin therapy.
• Data on the clinical outcomes of PCSK9 inhibitors in diabetic populations are still pending.

Conclusions:

• Ezetimibe represents a viable option for combination therapy in managing diabetic dyslipidemia due to its favorable risk profile.
• Further research and clinical outcome data are needed for emerging therapies like PCSK9 inhibitors in diabetic patients.
• Addressing residual CVD risk in diabetes requires careful consideration of combination therapy options.